News Boehringer back in cancer with Hernexeos approval Boehringer Ingelheim's bid to return to the oncology arena has been achieved with an FDA approval for lung cancer therapy Hernexeos.
News Ipsen charts $1.75bn course for Kartos acquisition Ipsen has agreed to buy cancer biotech Kartos Therapeutics for $450m upfront, adding a late-stage drug in the challenging MDM2 inhibitor class.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
